Literature DB >> 17133112

RNA interference technologies and their use in cancer research.

Alex Gaither1, Vadim Iourgenko.   

Abstract

PURPOSE OF REVIEW: Recently, RNA interference has evolved into a powerful research tool to functionally characterize genes. Genome-wide RNA interference reagents can study the loss-of-function phenotypes of candidate genes in the context of various disease model systems. In this review, we discuss the data from the most recent studies using RNA interference reagents with a focus on RNA interference-based genomic screening as a tool to expand our knowledge about the molecular basis of cancer. RECENT
FINDINGS: Tumorigenesis is the result of the progressive accumulation of mutations in genes controlling cell proliferation and death. Various genes carrying these alterations are known to be directly linked to tumor growth; however, how to translate this knowledge into effective chemotherapeutics, nontoxic to normal cells, is still a subject of intensive research.
SUMMARY: Loss-of-function studies offer a potential for validation of known and unrecognized tumor-associated targets. RNA interference-mediated gene knockdown can be exploited to study the reprogrammed circuitry of genes, discover gene interactions restricted to cancer cells and identify mechanisms of chemoresistance in cancer cells. In addition, the simultaneous use of cancer drugs and RNA interference also provides a paradigm to develop strategies to inactivate essential genes promoting neoplastic growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17133112     DOI: 10.1097/CCO.0b013e328011a8b0

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  6 in total

Review 1.  Systems approaches to polypharmacology and drug discovery.

Authors:  Aislyn D W Boran; Ravi Iyengar
Journal:  Curr Opin Drug Discov Devel       Date:  2010-05

2.  Systems pharmacology.

Authors:  Aislyn D W Boran; Ravi Iyengar
Journal:  Mt Sinai J Med       Date:  2010 Jul-Aug

3.  Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.

Authors:  S Rachagani; S Senapati; S Chakraborty; M P Ponnusamy; S Kumar; L M Smith; M Jain; S K Batra
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

4.  siRecords: a database of mammalian RNAi experiments and efficacies.

Authors:  Yongliang Ren; Wuming Gong; Haiyan Zhou; Yejun Wang; Feifei Xiao; Tongbin Li
Journal:  Nucleic Acids Res       Date:  2008-11-07       Impact factor: 16.971

5.  Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.

Authors:  Peter S Harris; Sujatha Venkataraman; Irina Alimova; Diane K Birks; Ilango Balakrishnan; Brian Cristiano; Andrew M Donson; Adrian M Dubuc; Michael D Taylor; Nicholas K Foreman; Philip Reigan; Rajeev Vibhakar
Journal:  Mol Cancer       Date:  2014-03-24       Impact factor: 27.401

6.  Lentiviral-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo.

Authors:  Javed Akhtar; Zhou Wang; Zhi Ping Zhang; Ming Ming Bi
Journal:  J Transl Med       Date:  2013-09-16       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.